Cargando…
Metabolism of the prodrug lisdexamfetamine dimesylate in human red blood cells from normal and sickle cell disease donors*
OBJECTIVES: Lisdexamfetamine dimesylate (LDX), a long-acting pro-drug psychostimulant, requires conversion to d-amphetamine for therapeutic activity. Conversion of LDX to d-amphetamine occurs primarily in the blood, specifically red blood cells (RBCs). These in vitro studies examine potential conver...
Autor principal: | Pennick, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Maney Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937656/ https://www.ncbi.nlm.nih.gov/pubmed/27536433 http://dx.doi.org/10.3109/21556660.2013.775132 |
Ejemplares similares
-
Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy
por: Ermer, James C., et al.
Publicado: (2016) -
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
por: Pennick, Michael
Publicado: (2010) -
Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells
por: Sharman, Johannah, et al.
Publicado: (2014) -
A Systematic Review of the Safety of Lisdexamfetamine Dimesylate
por: Coghill, David R., et al.
Publicado: (2014) -
Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)